Our news editors obtained a quote from the research, "First clinical trials performed with gamma retroviral vectors were promising and guaranteed clinical benefits to the patients. On the other hand, the outcome of severe adverse events as the development of hematological abnormalities highlighted the necessity to develop a safer platform to deliver the therapeutic gene. Self-inactivating (SIN) lentiviral vectors (LVVs) were studied to overcome this hurdle through their preferable integration pattern into the host genome."
According to the news editors, the research concluded: "In this review, we describe the recent advancements achieved both in vitro and at preclinical level with LVVs for the treatment of Wiskott-Aldrich syndrome (WAS), chronic granulomatous disease (CGD),
For more information on this research see: Lentiviral vectors for the treatment of primary immunodeficiencies.
The news editors report that additional information may be obtained by contacting G. Farinelli,
Keywords for this news article include: Biotechnology,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Tablets, Cars Drive AT&T Gains
- 2015 Mazda MX-5 Miata Is Fast and Eager
- Small Businesses Add 3 More Worries to Their List
- DOMA Tech Adding Jobs to Process VA Claims
- Apple Warns of China iCloud Attack
- Job Hunting Is Hard Work
- Tech Firms Flock to LA's 'Silicon Beach'
- Stocks Subdued After Gains Earlier in Week
- Ford, GM Expect to Report Strong Profits
- Consumer Prices Edge Up, Surprising Economists